Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Single Dose of Intravenous rhTNF-α and Liposomal Doxorubicin in Patients With Advanced Solid Tumors or Lymphomas

This study has been withdrawn prior to enrollment.
Sponsor:
Collaborator:
Johns Hopkins University
Information provided by (Responsible Party):
Ludwig Institute for Cancer Research
ClinicalTrials.gov Identifier:
NCT01490047
First received: December 8, 2011
Last updated: June 15, 2015
Last verified: June 2015
No Study Results Posted on ClinicalTrials.gov for this Study
Study was withdrawn before participants were enrolled.
  Study Status: This study has been withdrawn prior to enrollment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: No date given